Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Concordance of the Tuberculin Skin Test and T-Spot®.Tb Test Results in Kidney Transplant Candidates



Sherkat R1 ; Yaran M2 ; Shoaie P3 ; Mortazavi M4 ; Shahidi S4 ; Hamidi H4 ; Seirafian S4 ; Taheri S4 ; Farajzadegan Z2 ; Rostami S3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Acquired Immunodeficiency Research Center, Isfahan, Iran
  2. 2. Nosocomial Infections Research Center, Infectious Diseases and Tropical Medicine Research Center, Isfahan, Iran
  3. 3. Isfahan Kidney Diseases Research Center, Isfahan, Iran
  4. 4. Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Research in Medical Sciences Published:2014

Abstract

Background: Detection of latent tuberculosis infection (LTBI) in transplant candidates is very important. The tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are standard immunologic tools for LTBI detection. The aim of this study was to compare the TST results and T-SPOT®.TB test (a type of IGRAs) in kidney transplant candidates for the screening of LTBI and follow the patients with positive test for an activation of tuberculosis (TB) after transplantation and using anti-TB prophylaxis. Materials and Methods: This study was a prospective study and carried out in 44 renal transplant candidates from March 2010 to February 2011 in the teaching hospitals of Isfahan University of Medical Sciences, Iran. TST and T-SPOT®.TB test were performed and their results evaluated. Patients with a positive skin test and/or T-SPOT®.TB test were started on anti-TB prophylaxis and followed after transplantation for an activation of their LTBI for 1 year. Results: Overall, 8 (18.2%) patients were positive for TST and 6 (13.6%) patients for T-SPOT®.TB test. The agreement between TST and T-SPOT®.TB test was moderate (κ = 0.49, 95% confidence interval 0.145-0.839). The overall agreement between TST and T-SPOT®.TB test was 86%. No relation was found between the underlying diseases and TST or T-SPOT®.TB test positivity. Although isoniazid prophylaxis was used for patients with positive TST and/or T-SPOT®.TB test, one patient had reactivation of TB. Conclusion: In kidney transplant candidates both TST and T-SPOT®.TB test were comparable for the diagnosis of LTBI with reasonable agreement between the tests. However, further studies are needed to determine the ability of T-SPOT®.TB test to detect LTBI and to evaluate the need for prophylaxis in these patients.